CLINICAL OPERATION PHARMA SERVICES LIMITED

Executive Summary

Clinical Operation Pharma Services Limited shows a strong financial position for a micro-entity with significant growth in net assets and working capital over the last year. The company benefits from a clear ownership structure and timely compliance, supporting its ability to meet obligations. Approval is recommended with routine monitoring of liquidity and operational developments.

CLINICAL OPERATION PHARMA SERVICES LIMITED - Analysis Report

Company Number: 13951695

Analysis Date: 2025-07-29 16:08 UTC

1. Credit Opinion: APPROVE
   Clinical Operation Pharma Services Limited demonstrates a solid improvement in financial position over the last two years, showing strong net current assets and positive net assets as of 31 March 2024. The company is micro-sized, with minimal employees, which suggests limited operational complexity and risk. The director holds full control and appears to actively manage the company. No overdue filings or compliance issues are noted. Given the healthy balance sheet growth and clear ownership, the company appears capable of servicing debt and meeting commercial obligations.

2. Financial Strength:
   Financial statements reveal total net assets increased from £8,583 in 2023 to £47,002 in 2024, mainly driven by a substantial growth in current assets (£62,850) against a moderate increase in current liabilities (£23,184). Fixed assets have also grown but remain modest (£7,336). The company’s equity base is unleveraged and fully covers liabilities, indicating a strong capital structure for its size. The micro-entity status limits disclosure but available data points to a financially sound and well-capitalised entity.

3. Cash Flow Assessment:
   The company’s net current assets of £39,666 in 2024 reflect a comfortable liquidity position, enabling it to cover short-term liabilities nearly 2.7 times over. The working capital improvement from £5,900 in 2023 suggests enhanced operational cash flow or capital injections. With only one employee and controlled overhead, liquidity risks appear low. No cash flow statements are provided, but balance sheet indicators support adequate short-term financial flexibility.

4. Monitoring Points:

• Continued growth and maintenance of positive net current assets and net assets to ensure ongoing liquidity and solvency.
• Monitor any changes in director control or ownership concentration risks given sole control by a single individual.
• Watch for timely filing of accounts and confirmation statements to avoid compliance penalties.
• Observe expansion in fixed assets or employee count that might affect operational costs and capital needs.
• Assess revenue and profitability trends once more detailed P&L data become available to confirm sustainable earnings.